Danshen-Shanzha formula for the treatment of atherosclerosis: ethnopharmacological relevance, preparation methods, chemical constituents, pharmacokinetic properties, and pharmacological effects.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Glycitin Alleviates Myocardial Ischemia-reperfusion Injury By Suppressing Oxidative Stress and Apoptosis Through PI3K/Akt/NF-κB Pathway Modulation.Applied biochemistry and biotechnology · 2026
   Article
2. Physiologically Based Pharmacokinetic-Pharmacodynamic-Based Quantification of Exposure-Response for Sodium Tanshinone IIA Sulfonate in Normal and Cerebral Ischemia-Reperfusion Injury Rats.Biology · 2026
   Article
3. Cardiovascular Benefits ofFood science & nutrition · 2026
   Review
4. Comparative pharmacokinetics of periplocin and its four key metabolites in rats after oral administration of periplocin and cardiac glycoside extract fromFrontiers in pharmacology · 2026
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as